Bueno, Héctor2024-12-202024-12-202024-10-10Eur J Prev Cardiol. 2024 Oct 10;31(14):1679-1680.https://hdl.handle.net/20.500.12105/25928Dr Bueno receives research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Is predicting the risk of incident diabetes useful in patients with cardiovascular disease?Attribution-NonCommercial-NoDerivatives 4.0 International3919678831(14)1679-1680European Journal of Preventive Cardiologyopen access